Lonza Group AG stock (CH0013841017): Swiss CDMO trades softer after recent quarterly update

Lonza Group AG shares traded weaker on the SIX Swiss Exchange at midday on 05/28/2026, with the stock down around 0.7 percent at approximately 493.20 CHF according to finanzen.ch, as investors in Switzerland reassessed the most recent quarterly update and continued strategic adjustments in the portfolio. The move comes against the backdrop of Lonza’s role as a key contract development and manufacturing organization (CDMO) for global pharmaceutical and biotech customers, which keeps the stock in focus for both domestic and international investors.

The stock traded at roughly 493.20 CHF on 05/28/2026 on SIX Swiss Exchange (ticker: LONN), according to finanzen.ch as of that date, underscoring that the trading action is firmly anchored in the Swiss home market. In addition to its primary listing in Switzerland, Lonza is also actively followed on German trading venues, where the share is available for retail investors in EUR, adding a secondary point of reference for investors in German-speaking markets.

As of: 05/28/2026

By the editorial team - specialized in equity coverage.

Lonza Group AG: core business model

Lonza Group AG functions as a global CDMO partner that supplies development services, manufacturing capacity, and enabling technologies across biologics, small molecules, and advanced therapies to pharmaceutical, biotech, and nutrition customers worldwide.

Industry trends and competitive position

The industry environment around Lonza is shaped by sustained growth in outsourced manufacturing for biologics and advanced therapies, as large and mid-sized pharmaceutical companies continue to rely on specialized CDMOs to secure capacity and technical know-how for complex molecules. Within this context, Lonza competes with global peers in the CDMO space, including other large-scale biologics and small-molecule manufacturers, and its strategic portfolio reshaping is intended to align its asset base with areas of structurally higher demand in the life sciences value chain.

Conclusion

The softer trading in Lonza Group AG shares on 05/28/2026 reflects how Swiss and international investors are still processing the latest quarterly figures and the company’s ongoing portfolio measures in its CDMO operations. Against a backdrop of rising demand for outsourced biologics and advanced therapies manufacturing, Lonza’s positioning in the global CDMO industry remains central to how the stock is evaluated in the Swiss home market and beyond.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.